Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab with Bevacizumab and Pemetrexed in Elderly Advanced Non-Squamous NSCLC
NCT05273814Phase 1Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Aug 2022
- Primary completion
- Aug 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tislelizumab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Objective Response Rate at 2 years. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT05273814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05273814.